Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Platelet ADP receptor inhibitors

Inactive Publication Date: 2002-02-28
ALEXION PHARMA INC
View PDF0 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thrombotic complications are a major cause of death in the industrialized world.
Blood platelets, which normally circulate freely in the vasculature, become activated and aggregate to form a thrombus with disturbed blood flow caused by ruptured atherosclerotic lesions or by invasive treatments such as angioplasty, resulting in vascular occlusion.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Platelet ADP receptor inhibitors
  • Platelet ADP receptor inhibitors
  • Platelet ADP receptor inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0055] Compounds of formula (I), formula (II), formula (III), formula (IV), formula (V) and formula (VI) below represent one embodiment of the invention: 4

[0056] A is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, and alkylheteroaryl.

[0057] W is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

[0058] E is selected from the group consisting of H, --C.sub.1-C.sub.8 alkyl, polyhaloalkyl, --C.sub.3-8-cycloalkyl, aryl, alkylaryl, substituted aryl, heteroaryl, and substituted heteroaryl.

[0059] D is selected from the group consisting of NR.sup.1--(C.dbd.O)--R.s-up.2, --O--R.sup.1; 5

[0060] wherein:

[0061] R.sup.1 is independently selected from the group consisting of:

[0062] H, C.sub.1-C.sub.8 alkyl, polyhaloalkyl, --C.sub.3-8-cycloalkyl, aryl, alkylaryl, substituted aryl, heteroaryl, substituted heteroaryl, --(C.dbd.O)-C.sub.1-C.sub.8 alkyl, --(C.dbd.O)-aryl, --(C.dbd.O)-substitu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Poweraaaaaaaaaa
Currentaaaaaaaaaa
Currentaaaaaaaaaa
Login to View More

Abstract

Novel compounds of formula (I) to (VI), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and / or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I)-(VI), or a pharmaceutically acceptable salt thereof.

Description

[0001] The invention relates to novel compounds of formula (I), formula (II), formula (III), formula (IV), formula (V) and formula (VI) (hereinafter referred to as "formulae (I)-(VI)"), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and / or treatment of cardiovascular diseases, particularly those diseases related to thrombosis.DESCRIPTION OF THE RELATED ART[0002] Thrombotic complications are a major cause of death in the industrialized world. Examples of these complications include acute myocardial infarction, unstable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia / eclampsia, deep ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/381A61K31/4035A61K31/4365A61K31/443A61K31/4436C07D239/48A61K31/4439A61K31/497A61K31/501A61K31/506A61P7/02A61P9/00A61P9/10A61P43/00C07D239/22C07D239/50C07D333/34C07D401/04C07D401/12C07D401/14C07D405/12C07D405/14C07D409/12C07D409/14C07D417/12C07D495/04
CPCC07D239/22C07D239/48C07D239/50C07D333/34C07D401/04C07D401/12C07D405/12C07D409/12C07D409/14C07D417/12C07D495/04A61P43/00A61P7/02A61P9/00A61P9/04A61P9/10A61P9/14
Inventor SCARBOROUGH, ROBERT M.JANTZEN, HANS-MICHAELHUANG, WOLINSEDLOCK, DAVID M.MARLOWE, CHARLES
Owner ALEXION PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com